Can Fite Biopharma Ltd Company Profile (NYSEMKT:CANF)

About Can Fite Biopharma Ltd (NYSEMKT:CANF)

Can Fite Biopharma Ltd logoCan Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company's drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CANF
  • CUSIP: N/A
  • Web: www.canfite.co.il
Average Prices:
  • 50 Day Moving Avg: $1.71
  • 200 Day Moving Avg: $1.76
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -2,453.03%
  • Return on Equity: -57.94%
  • Return on Assets: -32.52%
Debt:
  • Current Ratio: 7.29%
Misc:
  • Beta: 1.2
 

Frequently Asked Questions for Can Fite Biopharma Ltd (NYSEMKT:CANF)

What is Can Fite Biopharma Ltd's stock symbol?

Can Fite Biopharma Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CANF."

How were Can Fite Biopharma Ltd's earnings last quarter?

Can Fite Biopharma Ltd (NYSEMKT:CANF) issued its earnings results on Tuesday, May, 31st. The company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03. Can Fite Biopharma Ltd had a negative return on equity of 57.94% and a negative net margin of 2,453.03%. View Can Fite Biopharma Ltd's Earnings History.

When will Can Fite Biopharma Ltd make its next earnings announcement?

Can Fite Biopharma Ltd is scheduled to release their next quarterly earnings announcement on Friday, November, 24th 2017. View Earnings Estimates for Can Fite Biopharma Ltd.

Who are some of Can Fite Biopharma Ltd's key competitors?

How do I buy Can Fite Biopharma Ltd stock?

Shares of Can Fite Biopharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Can Fite Biopharma Ltd (NYSEMKT CANF)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Can Fite Biopharma Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Can Fite Biopharma Ltd (NYSEMKT:CANF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Price Target History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Analysts' Ratings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Show:
DateFirmActionRatingPrice TargetDetails
10/18/2016Roth CapitalReiterated RatingBuyView Rating Details
8/29/2016Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
4/4/2016HC WainwrightReiterated RatingBuy$6.00View Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Earnings by Quarter for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Earnings History by Quarter for Can Fite Biopharma Ltd (NYSEMKT CANF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/24/2017        
5/31/2016Q116($0.09)($0.12)ViewN/AView Earnings Details
5/29/2015Q115($0.12)($0.04)ViewN/AView Earnings Details
4/8/2015($0.15)($0.20)ViewN/AView Earnings Details
12/2/2014($0.24)($0.10)ViewN/AView Earnings Details
9/3/2014($0.36)($0.20)ViewN/AView Earnings Details
5/30/2014($0.23)($0.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS

Dividends

Dividend History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Can Fite Biopharma Ltd (NYSEMKT:CANF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Latest Headlines for Can Fite Biopharma Ltd (NYSEMKT:CANF)
Source:
DateHeadline
seekingalpha.com logoCan-Fite Bio nabs patent in Korea for piclidenoson
seekingalpha.com - October 17 at 5:43 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Reports Patent in Korea for Piclidenoson in Treatment of Psoriasis - StreetInsider.com
www.streetinsider.com - October 17 at 5:43 PM
finance.yahoo.com logoCan-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
finance.yahoo.com - October 17 at 5:43 PM
businesswire.com logoCan-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, DC - Business Wire (press release)
www.businesswire.com - October 16 at 10:44 PM
finance.yahoo.com logoCan-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.
finance.yahoo.com - October 16 at 5:42 PM
businesswire.com logoCan-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on ... - Business Wire (press release)
www.businesswire.com - October 10 at 3:41 AM
finance.yahoo.com logoCan-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017
finance.yahoo.com - October 9 at 5:39 PM
finance.yahoo.com logoCan-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 5:09 PM
reuters.com logoBRIEF-Can Fite Biopharma files for mixed shelf of up to $50 mln
www.reuters.com - September 27 at 5:40 PM
businesswire.com logoCan-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of ... - Business Wire (press release)
www.businesswire.com - September 18 at 5:16 PM
finance.yahoo.com logoCan-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy
finance.yahoo.com - September 18 at 5:16 PM
finance.yahoo.com logoCan-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy
finance.yahoo.com - September 18 at 5:16 PM
businesswire.com logoCan-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update - Business Wire (press release)
www.businesswire.com - September 1 at 10:15 PM
seekingalpha.com logoCan-Fite Biopharma revenues up 25% in 1H
seekingalpha.com - September 1 at 5:11 PM
finance.yahoo.com logoCan-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update
finance.yahoo.com - September 1 at 5:11 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Receives $500K Milestone Payment From CKD Pharmaceuticals - StreetInsider.com
www.streetinsider.com - August 23 at 10:11 PM
seekingalpha.com logoCan-Fite received $500K milestone from Korean distribution partner Chong Kun Dang
seekingalpha.com - August 23 at 5:10 PM
finance.yahoo.com logoCan-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
finance.yahoo.com - August 23 at 5:10 PM
businesswire.com logoCan-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer - Business Wire (press release)
www.businesswire.com - August 9 at 5:06 PM
finance.yahoo.com logoCan-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
finance.yahoo.com - August 9 at 5:06 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says It Completed Human ... - StreetInsider.com
www.streetinsider.com - August 7 at 10:48 PM
reuters.com logoBRIEF-Can Fite Biopharma concluded cardiodynamic trial for piclidenoson
www.reuters.com - August 7 at 5:24 PM
seekingalpha.com logoCan-Fite wraps up cardiodynamic study on lead product candidate piclidenoson, Phase 3 studies on deck; shares slip 6%
seekingalpha.com - August 7 at 5:24 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says It Completed Human Cardiodynamic Safety Trial for Piclidenoson
www.streetinsider.com - August 7 at 5:24 PM
finance.yahoo.com logoCan-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
finance.yahoo.com - August 7 at 5:24 PM
seekingalpha.com logoCan-Fite on go with mid-stage study of namodenoson in fatty liver disease
seekingalpha.com - July 19 at 11:07 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient ... - StreetInsider.com
www.streetinsider.com - July 17 at 5:19 PM
finance.yahoo.com logoCan-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
finance.yahoo.com - July 17 at 5:19 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Concludes Successful Investigator Meeting for ACRobat Phase III Trial of Piclidenoson in ... - StreetInsider.com
www.streetinsider.com - June 10 at 9:14 PM
prnewswire.com logoCan-Fite Establishes Clinical Advisory Board for NAFLD/NASH - PR Newswire (press release)
www.prnewswire.com - June 5 at 9:04 PM
prnewswire.com logoCan-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update - PR Newswire (press release)
www.prnewswire.com - June 1 at 4:37 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: Jun 01 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - June 1 at 4:37 PM
reuters.com logoBRIEF-Can Fite Biopharma files for resale of up to 2.8 mln ordinary shares by selling shareholders - SEC filing
www.reuters.com - May 30 at 9:13 PM
streetinsider.com logoForm 6-K Can-Fite BioPharma Ltd. For: May 30 - StreetInsider.com
www.streetinsider.com - May 30 at 4:12 PM
seekingalpha.com logoCan-Fite Biopharma reports Q1 results
seekingalpha.com - May 30 at 12:14 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Files CTA in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis ... - StreetInsider.com
www.streetinsider.com - May 18 at 11:25 AM
reuters.com logoBRIEF-Can-Fite files clinical trial application in Canada for Piclidenoson
www.reuters.com - May 16 at 11:17 AM
seekingalpha.com logoCan-Fite files clinical trial application in Canada ahead of Phase 3 Piclidenoson study
seekingalpha.com - May 16 at 11:17 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Files CTA in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
www.streetinsider.com - May 16 at 11:17 AM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
www.streetinsider.com - May 4 at 4:15 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH - StreetInsider.com
www.streetinsider.com - May 3 at 8:20 AM
seekingalpha.com logoCan-Fite advancing late-stage study of piclidenoson in RA; shares ahead 9%
seekingalpha.com - April 26 at 3:00 PM
benzinga.com logo25 Stocks Moving In Wednesday's Pre-Market Session - Benzinga
www.benzinga.com - April 26 at 3:00 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Phase III ACRobat Trial in RA Approved by Institutional Review Board - StreetInsider.com
www.streetinsider.com - April 26 at 3:00 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Announces Phase III ACRobat Trial in RA Approved by Institutional Review Board
www.streetinsider.com - April 25 at 4:00 PM
prnewswire.com logoCan-Fite Reports 2016 Financial Results & Provides Clinical Update - PR Newswire (press release)
www.prnewswire.com - March 31 at 9:18 PM
reuters.com logoBRIEF-Can-Fite sees FY 2019 sales $1.4 billion
www.reuters.com - March 31 at 4:16 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says New Preclinical Data Shows Namodenoson Prevents Progression of Liver Fibrosis - StreetInsider.com
www.streetinsider.com - March 2 at 9:23 PM
msn.com logoCan Fite Biopharma (CANF) Jumps on Clinical Data
www.msn.com - February 28 at 4:22 PM
streetinsider.com logoCan-Fite BioPharma (CANF) Says New Preclinical Data Shows Namodenoson Prevents Progression of Liver Fibrosis
www.streetinsider.com - February 28 at 4:21 PM

Social

Chart

Can Fite Biopharma Ltd (CANF) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.